^
Association details:
| Biomarker: | ROS1 positive |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Anluoqing (envonalkib) (ALK inhibitor, ROS1 inhibitor, c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase I, dose-escalation and expansion study of TQ-B3139, a novel ALK TKI, in Chinese ALK or ROS1 positive advanced non-small cell lung cancer (NSCLC).
Published date:
05/13/2020
Excerpt:
TQ-B3139 was administered orally from 50mg~100mg qd and 200, 300, 400, 500, 600 and 800mg bid, using a PK-guided modified...totally 63 patients (59 ALK+, 4 ROS1+) were enrolled….Overall ORR was 73.0% (2 CR, 44 PR); DCR was 85.7% (8 SD)….Objective response was observed from dose level 200mg bid cohort, ORR and DCR at ≥200mg bid was 78.0% and 89.8%....TQ-B3139 was well tolerated in Chinese NSCLC patients with high antitumor activity.
DOI:
10.1200/JCO.2020.38.15_suppl.9585
Trial ID:
